98%
921
2 minutes
20
Chronic hepatitis B virus (HBV) infection is a major liver disease worldwide and its clinical manifestations are linked to immune response. The purpose of this study was to evaluate the relationship between selenium, copper, and zinc in comparison with transaminase level in chronic HBV patients. Serum samples of the HBV infected patients were obtained from Tooba medical center, Sari, Iran. Sixty patients were enrolled in this study (36 men and 24 women), mean age: 39.6 ± 12.2 years. The concentration of zinc, selenium, copper and transaminases were determined using an autoanalyzer system. Concentrations of selenium (0.273 ± 0.056 μg/dl) and zinc (2.1 ± 0.037) was elevated in patients with low transaminase levels as were significantly different in comparison with patients with high transaminase level (P<0.05). Serum copper concentration was similar in two groups of patients. Elevated levels of transaminase concentrations were independently associated with low zinc and selenium concentrations in chronic HBV patients. It is concluded that serum zinc and selenium levels are associated with less hepatic damage in chronic HBV patients and might have a protective role during liver injury.
Download full-text PDF |
Source |
---|
J Formos Med Assoc
September 2025
Department of Oncology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, 315000, China. Electronic address:
Clinics (Sao Paulo)
September 2025
Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
Introduction: Conventional mortality statistics that concentrate only on the underlying cause of death may offer a limited view of the complexity of this condition and not fully capture the true extent of mortality from hepatitis C.
Objective: To describe and analyze deaths due to chronic hepatitis C (CHC) in Brazil, as both a underlying and multiple cause of death, from 2000 to 2019.
Methods: This ecological study used data extracted from the Mortality Information System and descriptively analyzed causes of death and sociodemographic variables for the deceased.
J Viral Hepat
October 2025
Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.
View Article and Find Full Text PDFLiver Int
October 2025
Department of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Background And Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low- and middle-income countries. WHO guidelines recommend a half-adult dose for children (14-25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17-35 kg.
View Article and Find Full Text PDFAliment Pharmacol Ther
September 2025
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.